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COMMENTS
"WAR ON CANCER": WHY DOES THE FDA DENY ACCESS TO
ALTERNATIVE CANCER TREATMENTS?
Michael E. Horwin"
"I love purple.
I love yellow.
I love red.
Daddy, I love everything."
Alexander Horwin walking the halls of the Hematology-Oncology floor of
Children's Hospital Los Angeles, looking at the brightly colored paintings on the
walls while undergoing his second chemotherapy session in November, 1998. He
would die in his mother's arms three months later at the age of two and a half years
old
In February 1994, two and a half year-old Dustin Kunnari was diag-
nosed with a deadly brain tumor called medulloblastoma,' which was the
size of a golf ball.2 The neurosurgeon skillfully removed 75% of the tumor,'
. J.D. Candidate, December 2001, California Western School of Law; M.A., International
Business, Webster University, St. Louis 1990; B.A., Cultural Anthropology, University of
California, Santa Barbara 1984. Dedicated to my son Alexander Roy Horwin. He was denied
a potentially life saving treatment by the FDA on September 21, 1998. He died on January
31, 1999. He was two and a half years old and had his entire life before him.
1.
Medulloblastoma is a fast-growing tumor of the cerebellum, a part of the brain that
is located in the posterior fossa---the lower, rear portion of the skull. It tends to
spread (metastasize) throughout the brain and spine via the cerebrospinal fluid or
directly into areas adjacent to the cerebellum ... this tumor is most common in
children between three and eight years of age.
AMERICAN BRAIN TUMOR Ass'N, ABOUT MEDULLOBLASTOMA 1 (1998).
2. Patient Access to Alternative Treatments: Beyond the FDA Before the Government
Reform Committee of the House of Representatives. 105" Cong. (Feb. 4. 1998) thereinafter
Patient Access to Alternative Treatments-Kumnari Testimony] (statement of Mr. Jack Kun-
nari) available at http://www.house.gov/reformhearingshealthcare/fda2982..:4jk.htm (last
visited June 23, 2001).
3. Id.
1
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but surgery alone was not an adequate treatment4 and Dustin's parents were
referred to a chemotherapy trial.- The doctors informed the Kunnaris that the
side effects of the chemotherapy could include "bone pain, hearing loss, ir-
reversible damage to the kidney and bladder, destruction of the immune sys-
tem, learning disabilities, sterility, and, leukemia. ''6 "In addition, the doctors
could not name a single child who had done well following any of these
treatments."7 To Dustin and his family, this "cruel regimen with so little
hope"8 was less than promising.9
In April 1994, the Kunnaris traveled to Houston to consult with Stanis-
law Burzynski, M.D., Ph.D. Dr. Burzynski used an innovative and non-
toxic therapy to treat brain tumors." Because Dustin still had some tumor
left in his brain, Dr. Burzynski explained that the efficacy of his therapy
could be determined rapidly."2 If, after six weeks, the remaining tumor had
shrunk or disappeared then the treatment was working. 3 If the treatment
failed, the Kunnaris could have the orthodox oncologists administer the
more toxic therapies--chemo and radiation. For six weeks Burzynski's
treatment, called "antineoplastons," was administered to Dustin.'" After this
trial period was over, Dustin had a MRI (magnetic resonance imaging) of the
brain at a local hospital. Consequently, the Kunnaris were rewarded with
good news: the remaining tumor in Dustin's brain was gone. 5 The boy
stayed on the antineoplastons, but a year later, a second tumor appeared ap-
proximately one inch in diameter. 6 Dr. Burzynski increased the dose of his
therapy and the second tumor dissolved. 7 Today, over seven years from his
initial diagnosis, Dustin is a normal, healthy, cancer-free boy with no side
effects from the treatment. S
In August 1998, four years after Dustin was originally diagnosed, my
son, two-year-old Alexander Horwin was diagnosed with medulloblastoma,
the same tumor as Dustin Kunnari."9 Alexander was a strong, handsome and
4. AMERICAN BRAIN TUMOR ASS'N, supra note I, at 5.
5. Patient Access to Alternative Treatments-Kunnari Testimony, supra note 2.
6. Id.
7. Id.
8. Id.
9. Id.
10. Id.
II. Antineoplaston Therapy, at http:/Iwww.burzynskipatientgroup.org/antineop I lhtm
(last visited June 23, 2001).
12. Patient Access to Alternative Treatments-Kunnari Testimony supra note 2.
13. Id.
14. Id.
15. Id.
16. Id.
17. Id.
18. Id.
19. Physician Progress Note of Dr. Ronald Gabriel, Pediatric Neurologist (Aug. 10.
1998) (on file with author).
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intelligent child with curly brown hair and big brown eyes who could al-
ready speak English and French. He loved exploring the ocean and its mys-
terious tide pool animals with his Daddy. And he loved riding fast in his
stroller along the boardwalk as his Mommy roller-bladed behind him.
Surgeons removed the entire tumor, but told us that without further
treatment, this cancer would return and take Alexander's life. ' Like the
Kunnaris, we looked for the best treatment for our son, one that was the least
toxic and offered the greatest potential for survival and quality of life." After
extensively researching the medical treatment options, we also chose Dr.
Burzynski's therapy for Alexander.' This time, however, the outcome would
be different.
After bringing Alexander to Dr. Burzynski in Houston on September 21,
1998, we were stunned to learn that the FDA would not allow us to use this
therapy.23 Dr. Burzynski explained that the FDA controlled his protocols and
required children like Alexander to first undergo the "standard treatment" of
chemotherapy and/or radiation.' Once the cancer returned on the standard
treatment, then Burzynski could treat our son.'
This news seemed inconceivable to us. After enduring two brain surger-
ies, Alexander was now tumor-free and ready for the best cancer therapy that
would stop the disease from reoccurring. There we sat before Dr. Burzynski
in a brightly lit examination room in his clinic. In that clinic was the medi-
cine that could potentially save our son's life. The doctor was willing to treat
Alexander. We, Alexander's parents, wanted the treatment. Alexander
wanted to be well again. But even though all of the parties in interest were
willing, our decision had no weight or value. Instead, a decision made by a
bureaucrat two thousand miles away would trump the determination of the
parents and the doctor. This bureaucrat had never met Alexander, and did
not know anything about our son's medical history. He did not love Alexan-
der and yet his decision was final.
With no other treatment options available, we returned to Los Angeles
and reluctantly agreed to have chemotherapy administered to Alexander! 6
We were devastated to learn that if our son was one of the "lucky ones" to
survive, the side effects of chemotherapy could include:
20. Hearings on Integrative Oncolog)-Cancer Care for the New Milleniu-n-Before the
Committee of Government Reform, House of Representatives, 106' Cong. (June 7, 2000)
[hereinafter Hearings on Integrative Oncolog)-Horwin Testimony] (statement of Michael
and Raphaele Horwin), available at http://www.housc.gov/reform/heanngs/heahhcare/
00.06.07/horwin.htm (last visited May 20, 2001).
21. Id.
22. Id
23. Id
24. Id.
25. Id
26. Id.
3
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Low hemoglobin, low white blood cells, low platelets, infection, need for
blood transfusion, need for platelet transfusion, pain, nausea, vomiting,
hair loss, skin injury, heart damage, lung damage, liver damage, kidney
damage, loss of hearing, small stature, hormonal problems such as low
growth hormone or low thyroid hormone, infertility, second cancer, intel-
lectual 7decline, worsening of neurological symptoms, ineffectiveness, and
death 7
We continued to look for other options outside of the United States. 8
Three months after starting chemo, and while receiving the third "round" of
this therapy, Alexander started complaining of pain. "Mommy, I have pain
here and here," he repeated pointing to his head and back. On January 11,
1999, a CT scan of Alexander's head was done at Children's Hospital in Los
Angeles. The doctors assured us that they could see "nothing" and sent us
home. Alexander's pain persisted. Finally, on January 18, 1999, we de-
manded an MRI. To our horror it revealed thirty new tumors throughout
Alexander head and spine.29 We were told that Alexander had a "few days
perhaps" to live and he was discharged home from the hospital with decad-
ron, morphine and hospice care.3" Having endured chemotherapy and having
the cancer return, Alexander now met the FDA requirements and qualified
for Dr. Burzynski's therapy.3 Our son was so sick that we charted an air am-
bulance to fly him from Los Angeles to Houston.32 But the cancer was too
widespread. My son, Alexander Horwin, died on January 31, 1999. 3' He was
only two and a half years old.34
Although Dr. Burzynski's therapy has been in limited use since 1976"
and has cured a significant number of people with malignant brain tumors
when he has been permitted to do so;36 his therapy is still not FDA ap-
27. Id. In fact, according to a major medical treatise the standard cancer therapies are
"toxic," and the "most common causes of death in patients with cancer are infection (leading
to circulatory failure), respiratory failure, hepatic failure, and renal failure." ANTHONY S.
FAUCI ET AL., HARRISON'S PRINCIPLES OF INTERNAL MEDICINE 496, 499 (14" ed. 1998).
28. Hearings on Integrative Oncology--Horwin Testimony, supra note 20.
29. Id.
30. Id.
31. Id.
32. Id.
33. Id.
34. Id.
35. THoMAS D. ELIAS, THE BURZYNSKi BREAKTHROUGH 99-125 (1997). In the early
1970s, Burzynski was a research scientist at Baylor University in Houston, Texas. There, he
isolated various peptides and tested them in cell cultures and animal models. The peptides
stopped the growth of the cancers. He had also found that cancer patients have significant dif-
ferences in peptide content compared to healthy people. Burzynski then proceeded to use the
therapy on terminal cancer patients and had similar success. Id. See also Phase II Study of
Antineoplastons AJO and AS2-1 in Children with Primitive Neuroectodermnal Tumors-
Protocol BT-12, at http://catalog.com/bri/BTl2RE.html (last visited June 23, 2001).
36. Dr. Burzynski can only accept patients who meet a FDA approved clinical protocol
See Active Clinical Trials of Antineoplastons, at http://www.cancermed.com/clntrls.htm (last
visited Apr. 5, 2001). The overwhelming majority of these protocols require that children he
[Vol. 38
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proved.37 In 1983, Dr. Burzynski approached the FDA to initiate the approval
process.38 In 1993, Dr. Burzynski's Investigation New Drug application
(IND) was finally accepted and clinical trials began." Today, however, after
eight years of trials, the therapy is still not FDA approved. ' In fact, between
1994 (when two and a half year-old Dustin Kunnari was diagnosed) and
1998 (when two year-old Alexander Horwin was diagnosed), the FDA tight-
ened its criteria regarding which children can be treated with the non-
approved protocol."1 Since 1996, these criteria have required that children
with operable brain tumors must first undergo chemotherapy and/or radia-
tion and have the cancer return before Dr. Burzynski can treat them.'" Even
then, the FDA must personally accept the patient onto the protocol before
the therapy can begin. If the FDA says "no," there is no appeal.'3 Unfortu-
nately, Alexander was diagnosed after 1997, and therefore, the FDA required
that he first be treated with chemo and/or radiation before he could avail
himself of Dr. Burzynski's non-toxic therapy.
The FDA is charged with determining what drugs are approved for in-
terstate commerce and under what circumstances non-approved drugs may
be accessed." An examination of the FDA's position in relation to cancer
sufferers, especially children, will reveal that this agency has consistently
administered chemotherapy and radiation first and the tumor must return. However when the
tumor returns, most children only live a few weeks and do not meet the life expectancy re-
quirements of the FDA approved protocol-a horrific catch-22. See Phase 1I Study of Anti-
neoplastons A1O and AS2-1 in Children with Primitive Neuroectodermal Tumors-Protocol
BT-12 (§ 7.1.3, 7.1.2.4), at http://catalog.com/bri/BT12RE.html (last visited June 23, 2001).
When permitted, Dr.Burzynski has cured children with astrocytomas (see, for example, Mat-
thew Anderson), brainstem tumors (see, for example, Jessica Ressel), optic-hypothalamic
gliomas (see, for example, Paul Michaels), medulloblastomas (see, for example, Dustin Kun-
nari), and other brain tumors (see, for example, Shontelle Hiron). Our Stories: Burzynski Pa-
tient Group Directory, at http://www.burzynskipatientgroup.org/stories.htm (last visited June
23, 2001).
37. Active Clinical Trials of Antzineoplastons, at http://catalog.com/bri/clntrls.htm (last
visited May 31, 2001).
38. History Between Dr. Burzynski and FDA, at htp://catalog.comlbri/summary.htm.
(last visited May 29, 2001).
39. Id.
40. Active Clinical Trials of Antineoplastons, supra note 37.
41. Letter from Robert J. DeLap, M.D., Ph.D.. Director of the Division of Oncology
Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration. to
Dr. Burzynski, Burzynski Research Institute (paragraphs A. I., D.22.) (June 12. 1996) (on file
with the author).
42. Id See also Phase II Study of Antineoplastons A1O and AS2-1 in Children with
Primitive Neuroectodermal Tumors-Protocol BT-12 (§ 7.1.3. 7.1.2.4), at http://catalog.com
/bri/BT12RE.html (last visited June 23, 2001).
43. Patient Access to Alternative Treatments: Beyond the FDA Before the Government
Reform Committee of the House of Representatives, 105m Cong. (Feb. 4. 1998) [hereinafter
Patient Access to Alternative Treatments-nEmord Testimony] (statement of Jonathan W.
Emord, Attorney), available at http:llwww.house.gov/reformlhearingslhealthcarefda298
/2_4je.htm (last visited June 23, 2001).
44. 21 U.S.C. § 312 (2001), 24 C.F.R. § 312 (2001).
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and steadfastly come between patients and the non-FDA approved treat-
ments recommended by the patient's medical doctor. The juxtaposition of
the stories of the children introduced supra-Dustin Kunnari, who was for-
tunate enough to be treated and who is alive and healthy, and Alexander
Horwin, who was not treated, allowed only orthodox therapy, and who died
five months after being diagnosed-raises a number of disturbing legal is-
sues that will be discussed in this note.
Part I will introduce our nation's war on cancer and discuss how well
the war has been waged. Part II will survey how the law has consistently
limited patient access to non-FDA approved cancer therapies. It will discuss
the role of the FDA and the perspective of the U.S. Supreme Court. 5 Part III
will focus on the Access to Medical Treatment Act. Four Congresses have
attempted to pass this legislation that would allow patients access to non-
approved therapies, but the FDA has successfully argued against its passage
each time. The agency's medical-policy positions will be identified and cri-
tiqued.
Parts IV through VII focus on solutions. Overcoming the FDA's policy
arguments is essential to having the Access to Medical Treatment Act passed
which would allow children to have access to the therapy that has the best
chance of saving their lives. Therefore, these medical-policy suppositions
will be critically examined. In Part IV, the assumption that standard cancer
therapies are always best will be challenged. In Part V, the importance of re-
quiring thorough clinical testing of new cancer drugs will be considered. Part
VI will discuss whether bureaucrats should be placed in a position of trump-
ing the medical decisions of a patient and their physician. Part VII will ad-
dress the unsuspected role that economics may be playing in the multi-
billion dollar cancer industry. Finally, Part VIII will conclude by arguing
that the current state of the law in respect to cancer therapy is antithetical to
our country's core values.
I. THE WAR ON CANCER
On January 22, 1971, during President Nixon's State of the Union Ad-
dress, the President declared a "war on cancer." 6 He stated, "The time has
come in America when the same kind of concentrated effort that split the
atom and took man to the moon should be turned toward conquering this
dread disease. Let us make a total national commitment to achieve this
goal. 47
In the thirty years that have elapsed since this declaration, we have un-
fortunately fallen far short of this goal and the "war" continues to take an
45. U. S. v. Rutherford, 442 U.S. 544, 550 (1979).
46. President Richard Nixon's Annual Message to Congress on the State of the Union
(Jan. 22, 197 1), http://www.nixonfoundation.org/Research-Center/PublicPapers.cftn? Book-
Selected=1971 (last visited May 20, 2001).
47. Id.
[Vol. 38
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enormous number of casualties. According to the National Cancer Institute
(NCI), between 1973 and 1991, the age-adjusted" cancer death rate in-
creased.' From 1991 to 1998, the death rate began to decrease,' but the
overall percentage of change between 1973 to 1998 was 0%?' This year,
cancer will kill an average of 1,500 Americans a day." In fact, according to
the American Cancer Society "[cancer is [now] the second leading cause of
death in the US [sic], exceeded only by heart disease."" And perhaps most
disturbingly, cancer is now the leading cause of death by disease in chil-
dren.'
Like most wars fought by this country, this nation has not been hesitant
to spend large sums of money in pursuit of its goals. Since 1971, the NCI
has expended over 42 billion dollars for a cure." Progress has been made in
a minority of cancers,56 albeit at a cost of terrible suffering, in some cases.'
48. Age-adjusted means that the statistics are adjusted to reflect the change in the popula-
tion's ages. For example, one would expect that an older population would have a higher can-
cer death rate than a younger population. As the American population ages this change is fac-
tored into the numbers so that the death rate is independent of this aging.
49. NATIONAL CANCER INSTITUTE SEER CANCER STATISTICS REvIuw 1973-1998 TABLE
11-1 ALL SITES (INVASIvE) TRENDS IN SEER INCIDENCE AND US MORTALITY USING THtE
JOINPOINT REGRESSION PROGRAM, 1973-1998 WITH UP TO THREE JOINPOINTS BY RACE AND
SEx, available at http://seer.cancer.gov/PublicationsCSR 1973 1998/allsites.pdf (last visited
June 23, 2001).
50. Id.
51. NATIONAL CANCER INSTrTUTE SEER CANCER STATISTICS RevtMV 1973-1998 TABLE
1-10 SEER INCIDENCE AND U.S. MORTALITY TRENDS BY PRIMARY CANCER SITE AND SEX. ALL
RACES 1973-1998, available at http://seer.cancer.gov/PublicationslCSR1973_1998/overview/
overview5.pdf (last visited June 23, 2001).
52. American Cancer Society: Statistics, at
http://www3.cancer.orgtcancerinfo/sitecenter.asp?ctid=8&scdoc=4000&scs&scp=&scss
-0 (last visited Apr. 5, 2001).
53. Id.
54.
While cancer is only a minor cause of death in infancy (<1 year), it was the third
most common cause of death between the ages of I and 19 in 1997. following un-
intentional injuries and homicides. It constitutes about 8% of deaths between age I
and 19, and is the leading cause of death from disease at these ages.
American Cancer Society-Childhood Cancer, Introduction, at http:/lwww3.cancer.orgl can-
cinfo/sitecenter.asp?ct=1&ctid-8&scp=8.3.4.0032&scs--4&scss= I &scdoc=42014&pnt=2&la
nguage=english (last visited Apr. 5, 2001).
55. NATIONAL CANCER INSTITUTE PLANS & PRIORITIES FOR CANCER RESEARCH-
HIsTORICAL BuDGET INFORMATION, available at http:/P2002.cancer.gov/search?NS-search-
page=document&NS-rel-doc-name=Ilivel2002histbdgt.htm&NS-query= 1989&NS-search-
type=NS-boolean-query&NS-collection=Search_2002_Site&NS-docs-found=2&NS-doc-
number=2 (last visited June 23, 2001).
56. NATIONAL CANCER INsTrruTE SEER CANCER STATISTICS REv'titw 1973-1998 TABLE
1-15 TRENDs IN SEER INCIDENCE AND U.S. MORTALITY FOR SELECTED CANCER SITES. 1973-
1998, ALL RACES, MALES AND FEMALES, available at http:l/seer.cancer.govlPublications/
CSR1973_1998/overview/overview5.pdf (last visited June 23. 2001). According to the Na-
tional Cancer Institute, between 1973 and 1998 there has been a decrease in mortality for the
following cancers: oral cavity and pharynx, stomach, colon and rectum, pancreas. larynx. cer-
7
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Nonetheless, surgery, chemotherapy, radiation and hormone therapy are still
the four main modalities to treat various forms of cancer."
Three of these four modalities-surgery, radiation, and chemotherapy-
have been in use for decades. Surgery has been employed to excise tumors
for at least 500 years. 9 Similarly, treating cancer with radiation has been
practiced for nearly a century since the days of Madam Curie.' By the early
1900s, surgery and radiation (i.e. X-ray and radium) had already become the
"orthodox" treatments for cancer.' In the 1950s, chemotherapy was added to
the orthodox arsenal.' The fourth modality, hormone therapy, was added
more recently but is only effective in specific cancers such as breast cancer
and carcinoma of the prostrate. 63
After 500 years of surgery, 100 years of radiation, 50 years of chemo-
therapy, the application of hormone therapy, and despite spending billions of
dollars on research, cancer still took the lives of approximately two and a
half million Americans in the last five years.' This figure is more than six
times the total number of American Servicemen who died during World War
11.65
vix uteri, corpus and uterus, ovary, Hodgkin's disease, and leukemias. Id.
57. EWAN CAMERON & LINus PAULING, CANCER AND VITAMIN C 47 (1979).
58. American Cancer Society, Cancer Resource Center, Types of Treatment, available at
http://www3.cancer.org/cancerinfo/load-cont.asp?st=tr&ct= 1 &prevURL=load-cont.asp&lan
guage=ENGLISH (last visited Apr. 5, 2001). According to the American Cancer Society
(ACS) the types of treatment for cancer include surgery, radiation therapy, chemotherapy.
hormone therapy, and immunotherapy. However, according to the ACS, immunotherapy is
"most often used as an adjuvant therapy (along with or after another therapy) to add to the
anticancer effect of the main therapy." Id.
59. RALPH W. Moss, PH.D., THE CANCER INDUSTRY 43-45 (1999).
60. "Radiation therapy was introduced following the discovery of the radioactivity of
uranium in 1896 by Becquerel and of radium in 1898 by Marie and Pierre Curie. Use of radia-
tion therapy in the treatment of cancer first occurred in 1896..... MARGARET BARTON BURKF.
R.N., M.S., O.C.N., ET AL., CANCER CHEMOTHERAPY A NURSING PROCESS APt'ROACii 5
(1991). In 1917, a prominent New York physician who treated cancer wrote. "I have seldom
if ever come across a patient with cancer who had had any intelligent and prolonged attempt
to check its development by dietary, hygienic, and medicinal means, invariably the knife. X-
ray, and radium have been the only measures under consideration." L. DUNCAN BU.KI,.,Y.
A.M., M.D., CANCER-ITS CAUSE AND TREATMENT VOLUME II 31 (1917).
61. BULKLEY, supra note 60, at 31.
62. The chemotherapeutic approach to kill cancer cells with poisonous agents was in-
spired when the Allied Liberty Ship, the John E. Harvey exploded in the harbor of Bari, Italy
in 1943. The ship was carrying mustard gas and many of the sailors on board suffered or died
from the destruction of their white blood cells. This clinical reaction was noted by Navy doc-
tor, Peter Alexander and inspired synthesis of some of the first chemotherapeutic agents.
RALPH W. Moss, PH.D., QUESTIONING CHEMOTHERAPY 16(1995).
63. Androgen Deprivation is one example of hormone therapy. See, e.g., FIARRISON'S
PRINCIPLES OF INTERNAL MEDICINE601 (Anthony S. Fauci, M.D., et al. eds., 14 " ed. 1998).
64. American Cancer Society: Statistics, at
http://www3.cancer.org/cancerinfo/sitecenter.asp?ctid=8&scdoc=40000&scs=O&scp=0&scss
=0 (last visited Apr. 5, 2001).
65. THE WORLD ALMANAC 209 (1999). There were 407,316 battle deaths plus "other
deaths" for American Servicemen in WWII (2,500,000 / 407,316 = 6. I). Id.
[Vol. 38
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Some scientists have attributed this extraordinary death toll to a more
carcinogenic environment" and an aging population.' Others believe the
figure is independent of these factors." Nonetheless, it would seem rational
to allow terminal cancer patients for whom orthodox therapies are known to
be ineffective or debilitating to exercise freedom in selecting other modali-
ties to extend their lives or to alleviate their pain and suffering. Unfortu-
nately, the law currently does not permit such an exercise of personal choice.
II. HOW THE LAW HAS LIMITED ACCESS TO CANCER THERAPIES
A. The Federal Food, Dng, and Cosmetic Act
The Federal Food, Drug, and Cosmetic Act (FDCA) requires "substan-
tial evidence" of safety and efficacy of drugs before they are approved.' The
FDCA authorizes the FDA"0 to approve new drugs for interstate commerce."
66. American Cancer Society Environmental Cancer Risks, available at
http://www3.cancer.org/cancerinfo/sitecenter.asp?ctid=8&scp=8.2.1.40057&scs=3&scss=7&
scdoc -40093&language=english (last visited June 23, 2001). "Environmental factors, defined
broadly to include smoking, diet, and infectious diseases as well as chemicals and radiation.
cause an estimated three-quarters of all cancer deaths in the United States." id.
67. "The increases in the crude mortality rates due primarily to the aging of the popula-
tion." U.S. Cancer Mortality Rates by Different Age Standards 1973-1996, available at North
American Association of Central Cancer Registries-Education & Training/Online Educa-
tion, http://www.naaccr.org/Training/html/course2/M lthumbnails/Ries. 12.html (last visited
June 23, 2001).
68. For example, in respect to prostate cancer, one medical doctor has reported, "There is
no direct scientific proof that early detection of prostate cancer will decrease the mortality
rate." See Richard J. Babaian, M.D., Oncology Case Reports and Review, Prostate Cancer: A
Diagnostic Dilemma vol. 10, at http://www.roxane.com/pain/librarylNewsletters/
MDA/vlOn3.html (last visited June 23, 2001). With respect to female lung cancer the NCI has
stated, "Both the rate of new lung cancer cases and lung cancer deaths are rising for women."
See National Institute of Health: New Report on Declining Cancer Incidence and Death
Rates, available at http://www.ih.gov/newslpr/mar98/nci-12.htm (last visited June 23, 2001).
69. 21 U.S.C. § 355(d) (1994).
70. 21 C.F.R. § 5.10 (West 2001).
Originally, the FDA was organized under the Department of Agriculture. In 1940.
it was shifted to the Federal Security Agency. Finally, in 1953, it was transferred
to the Department of Health, Education and Welfare (HEW), wuch is now known
as the HHS. The FDA is part of the Public Health Service (PHS) group, which is
located within the HHS. The FDA is empowered to enforce the Federal Food.
Drug and Cosmetic Act, but it does not receive its authority from Congress di-
rectly. Rather, the legislation delegated the authority to the Secretary of HHS. who
is appointed by the President of the United States. The Secretary then delegates
this authority to the Assistant Secretary of HHS who oversees the PHS. This dele-
gation of authority is atypical for an important regulatory body. Review is compli-
cated further because the Commissioner of the FDA is appointed by the Secretary
of HHS, yet, the Commissioner reports to the Assistant Secretary of HHS ...
While the FDA reviews NDAs [New Drug Applications] and gives labeling and
marketing approval to qualified drugs, it does not conduct the actual investigation
or clinical trial. Furthermore, the FDA receives NDAs not only from commercial
9
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Drugs are defined very broadly as "articles (other than food) intended to af-
fect the structure or any function of the body of man" and "intended for use
in the diagnosis, cure, mitigation, treatment, or prevention of disease in man
or animals. 72 "Substantial evidence" means that "well-controlled investiga-
tions" were undertaken "by experts qualified by scientific training and ex-
perience to evaluate.., the drug."73 Violation of the FDCA by using drugs
that are not FDA approved can lead to seizure and destruction of the drugs in
question," injunctions to restrain further violations," and criminal penalties,
including imprisonment.76
B. FDA's Drug Approval Process
The process by which a new drug is approved is expensive, lengthy and
is carried out by the drug's sponsor, not the FDA. The "well-controlled in-
vestigations" used to determine "substantial evidence" include animal test-
ing and human testing.77 Typically, after the drug is tested on animals, the
drug's sponsor may submit an application for an investigational new drug
entities, but from governmental agencies as well, such as the NIlH.
Lynne Kessler Lechter, Regulatory Overkill and the AIDS Patient, I ALTO. L.J. Sci. & T,('II.
131, 150 (1991).
71. 21 U.S.C. § 321(b) (1994). "The term 'interstate commerce' means: (I) commerce
between any State or Territory and any place outside thereof, and (2) commerce within the
District of Columbia or within any other Territory not organized with a legislative body." Id
Interstate commerce also means drugs sold to patients who then transport them across state
lines, or drugs whose components or packaging are produced in another state before sale to
the patient. 21 U.S.C. § 355(a) (1994). See also U.S. v. Articles of Drug... Wans, 526 F.
Supp. 703, 707 (D.P.R. 1981).
72. 21 U.S.C. § 321(g)(1) (1994). Psychological/metaphysical approaches are not con-
sidered drugs and are not subject to FDCA regulation. Id.
73. 21 U.S.C. § 355(d) (1994).
As used in this subsection and subsection (e) of this section, the term 'substantial
evidence' means evidence consisting of adequate and well-controlled investiga-
tions, including clinical investigations, by experts qualified by scientific training
and experience to evaluate the effectiveness of the drug involved, on the basis of
which it could fairly and responsibly be concluded by such experts that the drug
will have the effect it purports or is represented to have under the conditions of use
prescribed, recommended, or suggested in the labeling or proposed labeling
thereof. If the Secretary determines, based on relevant science, that data from one
adequate and well-controlled clinical investigation and confirmatory evidence (ob-
tained prior to or after such investigation) are sufficient to establish effectiveness.
the Secretary may consider such data and evidence to constitute substantial evi-
dence for purposes of the preceding sentence.
Id.
74. 21 U.S.C. § 334 (1994).
75. Id. § 332.
76. Id. § 333.
77. Id. § 355.
[Vol. 38
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exemption (IND)." Once an IND is granted (and as long as it is not re-
voked), the drug's sponsor can begin human trials.' An Investigational Re-
view Board (IRB) is then appointed to oversee the three phases of human tri-
als. Phase I is used to determine the safety and relative toxicity of the drug at
various doses.' Phase II is used to determine efficacy as well as safety." In
Phase I, the new drug is compared to a placebo or another similar drug.'
The test subjects for all three phases are usually patients who have not bene-
fited from available drugs or treatments. After all three phases are complete,
the FDA determines whether the drug is safe and effective for its intended
use and whether it should be approved. 3
C. The Rutherford Court
FDA control over patients' access to cancer drugs was challenged in
Rutherford v. United States. ' In this case, terminally ill cancer patients sued
to enjoin the FDA from stopping the interstate shipment and sale of laetrile
on the grounds that it had not been approved for distribution under the
FDCA.' Laetrile, also known as amygdalin, is a naturally occurring sub-
stance found in apricot kernels and hundreds of other plants.' Reportedly, it
is has been used in the treatment of tumors for centuries beginning with the
Chinese 3,500 years ago.' The FDA determined that distribution of laetrile
in interstate commerce is illegal and subject to regulatory activity by the
Food and Drug Administration. Such determination, the court pointed out, is
reviewable by the district court under the Administrative Procedure Act, 5
U.S.C. section 701 et seq."
The district court held that the FDA's decision to stop the distribution of
laetrile was "arbitrary [and] capricious [and] that it represents an abuse of
discretion and is not in accordance with law."' The court stated, "[Tihe in-
dividual must be given maximum latitude in determining his own personal
destiny."'' The court also described the destructive effects of orthodox
treatment (radiation and chemotherapy) and held that individual decision-
78. 21 C.F.R. § 312 (2001).
79. Id.
80. Id.
81. Il
82. Id
83. For an overview of the FDA drug approval process see Lynne Kessler Lechter. Regu-
latory Overkill and the AIDS Patient, I ALB. L.J. Sci. & TECU. 131, 150 (199 i)
84. Rutherford v. U.S., 438 F. Supp. 1287, 1289-90 (W.D. Okla. 1977).
85. Id
86. Laetrile is a benzaldehyde cyamophoric glycosidc or nitriloside found in over 1,200
plants. ROBERT E. WLLNER, M.D., PH.D. TIlE CANCER SOLUTION 26 (1994)
87. Id at 25.
88. Id.
89. Rutherford, 438 F. Supp. at 1291.
90. Id at 1300.
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making "is the sole prerogative of the person whose body is being rav-
aged... .9, The court's analysis focused on the constitutional rights of citi-
zens; the right to privacy. The court held that by "denying the right to use a
nontoxic substance in connection with one's own personal health-care, [thel
FDA has offended the constitutional right of privacy."' The court con-
cluded:
Nonetheless, it appears uncontrovertible (sic) that a patient has the right to
refuse cancer treatment altogether, and should he decide to forego conven-
tional treatment does he not possess a further right to enlist such nontoxic
treatments, however unconventional, as he inds to be of comfort, particu-
larly where recommended by his physician?
The FDA appealed to the U.S. Supreme Court, which granted certiorari
and reversed." The Court based its analysis on deference to legislative intent
and statutory construction.' According to the Rutherford Court, the FDCA
"makes no express exception for drugs used by the terminally ill ... "96 The
Court explicitly held that "[e]xceptions to clearly delineated statutes will be
implied only where essential to prevent 'absurd results' or consequences ob-
viously at variance with the policy of the enactment as a whole."97 Appar-
ently the Court found nothing absurd in preventing dying patients access to a
non-toxic substance that might extend their lives or alleviate their suffering,
even though these patients have been labeled "terminal" by orthodox medi-
cine.
Furthermore, the Rutherford Court was sensitive to the authority of the
FDA. The Court validated the FDA's position that terminal cancer patients
must be ensured a therapeutic gain and that only FDA approval can assure
such a gain." The opinion also stated that if FCDA standards do not apply to
terminally ill patients, the FDA could ultimately lose its authority over all
drugs."
91. Id.
92. Id. at 1301.
93. Id. at 1299-1300.
94. U.S. v. Rutherford, 442 U.S. 544. 551,559 (1979).
95. Id. at 545.
96. Id. at 544.
97. Id. at 552.
98. Id. at 555-56.
Thus, the Commissioner generally considers a drug safe when the expected thera-
peutic gain justifies the risk entailed by its use. For the terminally ill, as for anyone
else, a drug is unsafe if its potential for inflicting death or physical injury is not
offset by the possibility of therapeutic benefit.
Id.
99. Id. at 557-58.
200 [Vol. 38
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Ill. THE ACCESS TO MEDICAL TREATMENT ACT
Since 1993, an increasing number of members of Congress have recog-
nized the inherent injustice in preventing cancer victims from having the
medical freedom to try to save their lives. In the words of one Congressman:
I do not see how the FDA is serving the public when, by its actions it pre-
vents a child with a brain tumor or a young woman with Non-Hodgkins
Lymphoma from getting a treatment these individuals and their families
have been informed about and have freely chosen to pursue. In essence,
the FDA is telling someone battling a disease like cancer that they cannot
have a potential life-saving treatment.'0
As a result, a bill has been repeatedly introduced in Congress entitled
"The Access to Medical Treatment Act.'"' This Act would allow a patient to
be treated by any licensed health care practitioner with any method of medi-
cal treatment the individual desires, so long as a comprehensive list of re-
quirements are met. These requirements mandate the petitioner to use "gen-
erally accepted principles and current information" to conclude that the
unapproved drug will not cause a danger to the patient, to inform the patient
that the drug is not approved, and to disclose any financial interest that the
practitioner may have in the drug."
Senator Bob Dole, an original co-sponsor of the Access to Medical
Treatment Act, has stated, "In a free market system, it seems to make sense
to make available non-harmful alternative medical treatments to individuals
who desire such treatments, without the Federal Government standing in the
way., ' o3
Congress has attempted to pass the Act from 1993 to 1999.' 04 Unfortu-
nately, the FDA has maintained that this Act would jeopardize lives because
it would not require clinical testing before prescribing a drug.'" This position
has convinced the majority of Congressmen and Senators that the risks out-
weigh the benefits in allowing patients the freedom to access the medical
care of their choice. This position and the assumptions on which it rests will
be discussed in detail infra.
100. 142 Cong. Rec. H4115 (daily ed. Apr. 29, 1996) (statement of Rep. Pallone).
101. S. 1955, 106 Cong. (1999); H.R. 746, 105 Cong. (1997); S. 578, 1050 Cong.
(1997;). H.R. 2019, 1040 Cong. (1995-96); S. 1035, 104 Cong. (1995-96); H.R .A696, 103°
Cong. (1993-94); H.R. 4499, 103" Cong. (1993-94) [hereinafter Bills).
102. S. 1955, 106' Cong. (1999).
103. Natural Health Village Legislation: Access to Medical Treatment Act, at
http://www.naturalhealthvillage.com/townhall/fedcral/access2med.html (last visited Apr. 5.
2001).
104. See Bills, supra note 101.
105. Patient Access to Alternative Treatments: Beyond the FDA Before the Government
Reform Committee of the House of Representatives, 105" Cong. (Apr. 22. 1998) Ihereinafter
Patient Access to Alternative Treatments-Friedmnan Testimony) (statement of Michael A.
Friedman, M.D. Lead Deputy Commissioner Food and Drug Administration) available at
http://www.fda-gov/olaltherapy.htm (last visited June 24. 2001).
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A. The Inherent Medical-Policy Position
The FDA's policy objective is to ensure that cancer sufferers only em-
ploy the so-called "proven methods" and are not deceived into using non-
approved therapies that can be ineffective and potentially dangerous. This
concern is summarized in the Rutherford opinion: "
Since the turn of the century, resourceful entrepreneurs have advertised a
wide variety of purportedly simple and painless cures for cancer, including
liniments of turpentine, mustard, oil, eggs, and ammonia; peat moss; ar-
rangements of colored floodlamps; pastes made from glycerin and lim-
burger cheese; mineral tablets; and 'Fountain of Youth' mixtures of
spices, oil, and suet.'0 7
This policy is also reflected in the California Health and Safety Code:
"It is established that accurate and early diagnosis of many forms of cancer,
followed by prompt application of methods of treatment that are scientifi-
cally proven, either materially reduces the likelihood of death from cancer or
may materially prolong the useful life of individuals suffering there from."'0 U
And finally, FDA representatives have testified that they must play a crucial
role in determining what drugs are available so patients are "protected from
untested and unproven products."'"
B. Passing the Access to Medical Treatment Act
The Access to Medical Treatment Act would allow cancer sufferers to
choose the most appropriate medical treatment with the help of their physi-
cian. This Act, however, will not be passed unless the underlying medical-
policy assumptions inherent in the Supreme Court's decision, state statutes,
and the FDA's position are addressed. These assumptions are:
Standard therapies represent a patient's best chance for a cure;
Thorough clinical testing of cancer therapies is always necessary;
Bureaucrats should be placed in a position of trumping the medical deci-
sions of a patient's own physician; and
Politics and economics play no role in determining what cancer treatments
are labeled "proven" by the FDA, the pharmaceutical industry or the large
institutional cancer centers.
Each one of these medical-policy assumptions will be discussed inJ'a.
106. See Rutherford, 442 U.S. at 558.
107. Id.
108. CAL. HEALTH & SAFETY CODE § 109250 (West 1996).
109. Patient Access to Alternative Treatments-Friedmnan Testimony, supra note 105
202 [Vol. 38
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IV. ARE STANDARD CANCER THERAPIES ALWAYS BEST?
Do standard cancer therapies represent a patient's best chance for a
cure? The American Cancer Society statistics cited supra demonstrate that
despite widespread use of the proven therapies of surgery, radiation, chemo-
therapy, and hormone therapy, 1,500 people will die of cancer today and
every day."' An example demonstrates this point.
A. Example-Pediatric Brain Cancer
According to the FDA, radiation and chemotherapy are considered the
"standard" therapy for treating pediatric brain cancers such as medulloblas-
toma."' That is why the FDA refused to allow Dr. Burzynski to treat our son,
Alexander Horwin, introduced supra. But, according to oncologists, these
"proven" or standard therapies are ineffective. Their medical journals con-
tain admissions like the following: "[In] medulloblastoma, the most common
primary tumor of the CNS [central nervous system] in childhood ... [t]he
role of adjuvant chemotherapy is unclear ... virtually no cures are re-
ported.""' "Aggressive treatment of medulloblastoma, the most common pe-
diatric brain tumor, has not improved survival."...3 .IT~he absolute benefit of
chemotherapy for the treatment of medulloblastoma in childhood is, as yet,
not proven.""' "The median time to progression [return of the tumor] was 6
months."'"5 "For many years, chemotherapy has been utilized for the treat-
ment of malignant brain tumors with minimal success.""' "The outcome for
the majority of children with malignant brain tumors remains poor, despite
surgery, irradiation and conventional chemotherapy." ''H
In comparison, Dr. Burzynski's innovative, non-toxic, but non-FDA-
approved cancer therapy for brain tumors has been described as significantly
110. See American Cancer Society Statistics, supra note 52.
111. Chairman Dan Burton Introduces the "Thomas Navarro FDA Patient Rights Act,"
at http:lwww.house.govlreforrnlFDAPatientRightsAct.htm [hereinafter "Tiomas Navarro
FDA Patient Rights Act] (last visited Apr. 5, 2001).
112. H.S. Friedman & S.C. Schold Jr. Rational Approaches to the Chemotherapy of Me-
dulloblastom, 4 NEUROL CLIN. 843-53 (1985).
113. M.D. Weil, et al., Influence of a Child's Sex on Medulloblastoma Outcome. 279
JAMA 1474-76 (1998).
114. S. Attard-Montaho, et al., Is There a Danger in Delaying Radiotherapy in (hld.
hoodMedulloblastoma?, 789 BR. J. RADIOL. 807-13 (1993).
115. J. R. Geyer, et al., Survival of hIfants with Primitive Neuroectodermal Janors or
Malignant Ependymomas of the CNS Treated with Eight Drugs in I Day A Report from the
Childrens Cancer Group, 12 (8)J. C.INICAL ONCOL. 1607-15 (1994).
116. M.D. Prados & C. Russo, Chemotherapy of Brain Tumors. 14(1) SL\it.%W. SUG
ONCOL. 88-95 (1998).
117. J. L. Finlay, The Role of High-Dose Chemotherapy and Stem Cell Rescue in the
Treatment of Malignant Brain Tumors, BONE MARROW TR,%NSPI.A, r (1996 & Supp 3. 18:S I -
5).
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more successful than the "proven" therapies."' In 1997, Robert E. Burdick,
M.D., a Seattle oncologist and faculty member of the University of Wash-
ington Medical School, wrote:
It is very rare, currently, to ever get a complete remission or cure in a pa-
tient who has a malignant brain tumor using our standard modalities of
surgery, radiation and chemotherapy .... As a rough estimate, neurosur-
geons do well to cure I in every 1,000 brain cancer patients they operate
on. Radiation therapy slows the growth of adult tumors gaining perhaps
one month of life and again may result in a cure in only I in 500-1,000 pa-
tients. . . . Similarly, chemotherapy research, despite 30 years of clinical
trials, has not resulted in the development of a single drug or drug combi-
nation that elicits more than an occasional transient response in primary
brain tumors... . The responses [with Burzynski's treatment] are far in
excess of any prior series of patients published in the medical literature...
a response rate here is an astounding 33%. Such remission rates are far in
excess . . . of anything that I or anyone else has seen since research work
on brain tumors began." 9
Even the National Cancer Institute (NCI) agrees that Burzynski's ther-
apy works. '20 In a 1991 internal memo from Dr. Michael Friedman, Associ-
ate Director of Cancer Therapy Evaluation Programs, to Dr. Bruce Chabner,
Director of the Division of Cancer Treatment, Friedman wrote that Burzyn-
ski's treatment is comprised of "well defined, pure chemical entities ...
[and] [t]he human brain tumor responses are real."''
Despite these findings by oncologists and the NCI, Dr. Burzynski's
therapy is not accessible. Surgery, radiation and chemotherapy are still the
only therapies the FDA allows children to use until their cancers return, but
by then it is often too late. 2' Thus, to represent these approved therapies as a
cancer victim's only hope is disingenuous.
B. Is the Cancer Paradigm of Mainstream Medicine Infallible?
For decades, orthodox medicine has opined that an aberrant cell causes
cancer.' Those who believe that the competence of an individual's immune
system is the more decisive factor in cancer have challenged this view. '
118. The Burdick Report (Feb. 19, 1997), available at http://www.burzynskipatleit
group. org/burdickreport.htm (last visited June 24, 2001).
119. Id.
120. Memorandum from Dr. Michael Friedman, Associate Director, Cancer Therapy
Evaluation Programs, to Dr. Bruce Chabner, Director, Division of Cancer Treatment (Oct. 3 1.
1999), available at http://www.cancermed.com/friedman.html (last visited Apr. 5, 2001).
121. Id.
122. Thomas Navarro FDA Patient Rights Act, stupra note I l.
123. Professor Robert A. Weinberg describes cancer cells as "deaf to the usual controls
on proliferation" and able to "follow their own internal agenda for reproduction." Robert A
Weinberg, How Cancer Arises, 275 Sci. AM. 62, 63 (1996).
124. For example, according to Dr. Robert Millner, "[Tlhe repair and support of our n-
mune system with natural remedies that do not interfere with normal processes is the best ra-
[Vol. 38
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Today, this controversial perspective is becoming more mainstream as or-
thodox medicine has begun testing immune and "biological therapies."'"
Nonetheless, for many years such therapies were summarily rejected and
those practitioners who used corresponding approaches were ostracized. The
following example illustrates this point.
C. Professor Andrew C. Ivy M.D.
Professor Andrew C. Ivy, M.D. enjoyed an impeccable reputation as a
researcher, scientist and physician.26 He taught thousands of medical stu-
dents, had been involved in over 1,300 medical studies, and had discovered
several of the body's hormones. 7 In 1946, he was appointed as the sole
Medical Scientific Consultant to the U.S. Military Tribunal No. I at Nurem-
berg to serve as "an expert witness on scientific and ethical subjects." '' Af-
tional and scientific approach (for the cure of cancer and degenerative diseases)." ROBERT E
WnL.NER, M.D., PH.D. THE CANCER SOLUTION 11 (1994).
125. NCI Fact Sheet: Biological Therapies: Using the lmnune System To Treat Cancer.
available at http://cancer.med.upenn.edu/pdq-htmlU6/engU600072.html (updated Apr 2000)
126. The American Physiological Society, 17th APS President (1939-1941), Andrew C
Ivy, (1893-1978), at http://www.the-aps.org/about/presidentsintroaci.htm (last visited Apr. 5,
2001). The following comes from the American Physiological Society's biography of Dr. Ivy.
Andrew Conway Ivy served as president of the Society for the two-year term just
before the dislocations caused by World War I1. He had previously been secretary
for five years. Born in Farmington, Missouri. he was educated prmnly at the
University of Chicago, where he received his Ph.D. degree in 1918 under A. J
Carlson. He received an M.D. degree from Rush Medical College in 1922 while
associate professor of physiology at Loyola University School of Medicine (1919-
23). Other academic positions were at the University of Chicago (associate profes-
sor, 1923-25), Northwestern University Medical School (head of the Division of
Physiology and Pharmacology, 1926-45), the University of Illinois (vice-president.
1946-53; and distinguished professor of physiology, 1953-62). and Roosevelt Uni-
versity (research professor of biochemistry, 1962-66). He also served as scientific
director of the Naval Medical Research Institute (1942-43). executive director of
the National Advisory Cancer Council (1947-51). and director of the Ivy Cancer
Research Foundation. Author of approximately 2,000 scientific articles (over 1.500
by 1955), his contributions were primarily in gastrointestinal physiology and
pharmacology but also included the physiology of reproduction, applied physiol-
ogy (aviation medicine), and physiological resistance to cancer. His interest in
cancer increasingly dominated his career after 1946. This included work on a
highly controversial drug, 'krebiozen,' which led to a temporary estrangement
from his colleagues at APS. During the mid 1970s. however, he began attending
Society meetings again and displayed the same vigor characteristic of him in for-
mer years. After his term as president, Ivy continued to serve the Society on the
Board of Publication Trustees (1945-48), and in this capacity lie is credited with
recruiting Milton 0. Lee, who in 1947 became the first employed executive secre-
tary-treasurer of the Society as well as managing editor of the publications
Id.
127. HERBERT BAILEY, A MATTER or LiFE OR Di,- ni 28-29 (1958)
128. ALEXANDER MrrsCHERLICH & FRED MiEu.Le, DocToRs oF INt.AMY, "itti STORY Oi1
THE NAZI MEDICAL CReMES IX (1949). "[T]he [U.S.] Secretary of Warl asked the Board of
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ter the war, Ivy became the vice-president of the University of Illinois where
he ran that university's large medical school.'29 He was also named Execu-
tive Director of the National Advisory Cancer Council and a director of the
American Cancer Society. 3 ' Dr. Ivy's name can also be found in most stan-
dard medical dictionaries.1
3
'
For over twenty years, Ivy taught his medical students that rare sponta-
neous remissions of cancer found in the medical literature indicated the exis-
tence of some chemical substance produced in the body which acts as a de-
fender against this disease.'3 2 In 1949, Ivy began testing a cancer treatment
called krebiozen.'33 Invented by Dr. Stevan Durovic,'3" krebiozen was made
from a hormone that horses generated when they had been exposed to a fun-
gus (Actinomyces bovis) that caused a cancer-like disease called "lumpy
jaw."'35 The results of the therapy were very encouraging. Reportedly, the
first terminal cancer patients found their tumors disintegrating after being
administered the experimental drug.'36 In 1954, Dr. Ivy collated, analyzed
and evaluated the various reports from physicians who had used krebiozen
on terminal cancer patients. A summary of this medical report indicated, "In
S11 of 226 externally measurable cases, or in about 50% of these cases, the
tumors decreased in size."'3 7
The FDA never approved krebiozen.'38 In April 1965, a cancer victim
named Geraldine Ray sued the federal government on the grounds that its
prohibition of krebiozen was unlawful and unconstitutional. "9 Her amended
complaint was dismissed, and following her death in October 1965, her es-
tate appealed. The Court of Appeals for the Seventh Circuit affirmed the de-
cision, holding that the doctrine of primary jurisdiction applied and the FDA
was in the best position to decide whether krebiozen should be accessible or
not.'
In 1967, Dr. Allen Rutherford and a number of cancer patients who had
been treated with krebiozen appealed a district court's decision to dismiss
Trustees of the American Medical Association [AMA] to nominate a medical scientist to
serve as a consultant to the Nuremberg trial of Nazi physicians." Id. at ix. From the tens of
thousands of AMA physicians, this organization chose Dr. Ivy.
129. BAILEY, supra note 127, at 28-29.
130. Id. at 30.
131. DORLAND'S ILLUSTRATED MEDICAl. DICTIONARY 1611 (25h ed. 1974). Ivy invented
a test he used to measure platelet and capillary function. Id.
132. BAILEY, supra note 127, at 31.
133. The word "Krebiozen" was compounded from Greek terms meaning "that which
regulates growth." BAILEY, supra note 127, at 38-39.
134. Durovic was a Yugoslav refugee who had been living in Buenos Aires. Id. at 10. 1Ic
had worked at the Pasteur Institute in Paris prior to WWII. Id. at 16.
135. Id. at 22.
136. Id. at 39-43.
137. HERBERT BAILEY, KREBIOZEN-KEY TO CANCER? 300 (1955).
138. Tutoki v. Celebrezze, 375 F.2d 105, 107 (7th Cir. 1967)
139. Id. at 106.
140. Id. at 107.
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their suit against the American Medical Association (AMA)."' The suit al-
leged that the AMA had taken an active role in working with the FDA to in-
terfere with the approval and national distribution of krebiozen. The court
affirmed the lower court's decision on the grounds that the court had no ju-
risdiction to decide whether the FDA had placed unreasonable conditions on
approval of the product. 1
3
At the time the United States government was outlawing the interstate
shipment of krebiozen, it was widely accepted amongst orthodox medicine
that human beings possessed no specific resistance to cancer in their blood.
Hence, the notions that a substance from the blood of horses could arrest or
cure cancer in people sounded like quackery to government scientists.
Today, Drs. Ivy and Durovic's insights may be better appreciated. In the
last fifteen years, mainstream science has caught up with the wisdom of
these two innovative physicians. According to a leading medical treatise,
"Animal studies have conclusively shown that the immune system can rec-
ognize and eliminate malignant tumors in vivo.'" In recent years, billions of
dollars have been invested in isolating and synthesizing interleukin, inter-
feron, and other cytokines-all natural immune-related substances which
can kill or arrest cancer and that are found in the blood of mammals includ-
ing horses and man.''
D. Stanislaw Burznski M.D. Ph.D.
The Burzynski therapy is also based on substances that naturally exist in
healthy people." 6 As a research scientist at Baylor University of Medicine in
the 1970's, Dr. Burzynski observed that people without cancer carry specific
peptides in their blood and cancer patients are often missing these pep-
141. Rutherford v. AMA, 379 F.2d 641. 642 (7th Cir. 1967).
142. ld
143. Id. at 643.
144. HARRISON'S PRINCIPLES OF NTERNAL MEDICINE 535 (Anthony S Fauct. et al eds.
14 ed. 1998).
145. For examples of immune related substances found in man, see NO Fact Sheet Bio-
logical Therapies: Using the Inmmune System To Treat Cancer, available at
http://cancer.med.upenn.edu/pdq-html/6/engl/600072.html (Updated Apr 2000) For exam-
ples of immune related substances found in horses, see B. Von Rechenberg, et al.. Upregula-
tion of mRNA of Inrerleukin-1 and -6 in Subchondral CYstic Lesions of Four Horses, 33
EQUINE VETERINARY J. 143-49 (2001) and G. Grunig and D.F. Antc.ak. Horse Trophoblasts
Produce Tuor Necrosis Factor Alpha But Not Interleukin 2. Interleukin 4 . or Interferon
Gmmna, 52 BIOLOGICAL REPRODUCTION 531-39 (1995). "'Messenger RNA for interleukin 2
(IL-2), interleukin 4 (IL-4), and interferon gamma (IFN gamma) was detected in endometnal
tissues, unstimulated peripheral blood lymphocytes, and control kidney tissue, but not in tro-
phoblasts." Id. For an example where a horse blood product was used in the treatment of hu-
man disease see K.F. Mangan, Interferon-induced Aplasia: Evidence for T-cell-Mediated
Suppression of Hematopoiesis and Recovery after Treatment with Horse Anthuiman Thztno-
cyte Globulin, 19 AM. J. HEMATOLOGY 401-13 (1985).
146. RALPH W. MOSS, PH.D., THE CANCER INDUSTRY 289-92 (1999)
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tides.' 7 By synthesizing these peptides and administering them to cancer pa-
tients, many cancers are dissolved or halted from growing.'' Perhaps this
idea sounded ludicrous in 1976, but today, the value of these peptides in de-
stroying cancer cells has been proven in pathology laboratories throughout
the world. 9 Nonetheless, mainstream oncologists still challenge Dr. Burzyn-
ski's approach and, as such, his non-toxic cancer treatment is still not ap-
proved for use even though the FDA has accelerated its approval of chemo-
therapy to treat brain tumors. 5
E. The Ramifications for Changing Paradigms
Mainstream medicine's paradigm of cancer as a disease of an aberrant
cell is slowly being challenged. Today, orthodox researchers are learning
how an individual's immune system can regulate cancer. Unfortunately, for
the last one hundred years, orthodox science has made a monumental as-
sumption that its aberrant cell paradigm was the only correct one. Millions
of people may have died of cancer due to this presumption. Is it appropriate
to assume that the paradigm embraced by government scientists today is ac-
curate, thereby giving them unrestrained power to act on their supposition?
V. RELEVANCE OF CLINICAL TESTING
The FDA states that one reason why the Access to Medical Treatment
Act is dangerous to patients is because it would not require clinical testing
for carcinogenicity, toxicity or efficacy.'' Each one of these arguments will
be analyzed infra.
147. Id. For a thorough discussion of Burzynski's treatment, see the 209 medical article,
written by independent scientists listed in Publications on Antineoplastons and their Active
Ingredients by Scientists Independent of the Burzynski Research Institute, available at
http://catalog.comlbri/pubsi.htm (last visited June 24, 2001). Dr. Burzynski's 107 journal ar-
ticles are referenced in Publications by Stanislaw R. Burzynski, M.D., Ph.D. available at
http://catalog.com/bri/pub.htm (last visited June 24, 2001).
148. When permitted, Dr.Burzynski has cured children with astrocytomas (Matthew An-
derson), brainstem tumors (Jessica Ressel), optic-hypothalamic ghomas (Paul Michaels).
medulloblastomas (Dustin Kunnari), and other brain tumors (Shontelle Hiron). Our Stories
Burzynski Patient Group Directory, at http://www.burzynskipatientgroup.org/stories.htm (last
visited June 23, 2001).
149. See also T.E. Witzig et al., Induction of Apoptosis in Malignant B Cells by I'henvl-
butyrate or Phenylacetate in Combination with Chemotherapeutic Agents 2 CLINICAL CANC'hR
RESEARCH 681-92 (2000) and J.A. DiGiuseppe et al., Phenylbutyrate-Induced ( Arrest and
Apoptosis in Myeloid Leukemia Cells: Structure-Function Analysis, 8 LLUKEMIA 1243-53
(1999).
150. Schering-Plough Announces FDA Approval of Teniodar (Ternozolornide) Capsules
for patients with Refractory Anaplastic Astrocytoma,, available at http://www.sch-
plough.com/news/business/1999/8-I 1-99.html (last visited Apr. 5, 2001).
15 1. Patient Access to Alternative Treatments-Friednan Testimony, supra note 105.
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A. Testing for Carcinogenicir
No one wants to take a drug that can or may cause cancer. However, re-
quiring carcinogenicity testing in the context of cancer is disingenuous for at
least three reasons.
First, there is no logic in stopping cancer patients from accessing a ther-
apy because they could get cancer from it in five, ten or twenty years. A
small theoretical risk of developing cancer in the future carries little signifi-
cance compared to the reality that the individual is dying of cancer now.
Second, the requirement for carcinogenicity testing suggests that all the
products that are approved by the FDA are tested for carcinogenicity. This is
not true. For example, none of the thirty vaccines that millions of children
are administered before they are eighteen months old have been tested for
carcinogenicity." In fact, these vaccines contain known and suspected car-
cinogens such as mercury and formaldehyde, but are not tested.'" Despite
cancer being the leading cause of death by disease in children," the FDA
permits healthy children to be injected with untested products that contain
known and potential carcinogens, yet prohibits cancer victims with little
time left to take a similar risk.
Third, the FDA admits "[Miany conventional drugs 'routinely used' to
treat cancer patients can have serious or life-threatening effects.""' In fact,
many chemotherapy drugs are listed as known or suspected human carcino-
gens with the National Toxicology Program," whose participating agencies
include the FDA, NIH, and CDC.'" The FDA's position, therefore, is that a
152. PHYSICIANS' DESK REFERENCE 1510, 1520. 1528, 1819, 1737. 1740. 1833, 1843,
1908, 2316, 2320, 2333, 3048 (53"4 ed. 1999) [hereinafter P.D.R.]. For a list of the 30 vac-
cines, see Center's for Disease Control Recommended Childhood Innunization Schedule
United States, January-December 2001. The 30 vaccines are administered in 20 injections. Id.
153. P.D.R., supra note 152.
154.
While cancer is only a minor cause of death in infancy (<1 year), it was the third
most common cause of death between the ages of I and 19 in 1997, following un-
intentional injuries and homicides. It constitutes about 8% of deaths between age I
and 19, and is the leading cause of death from disease at these ages
American Cancer Society,-Childhood Cancer, Introduction. at http:J/www cancer org/ can-
cerinfo/sitecenter.asp?ct= 1&ctid8&scp=8.3.4.40032&scs=-4&scss= 1 &scdoc=42014
&pnt=2&language=english (last visited Apr. 5, 2001).
155. Patient Access to Alternative Treatrients-Friedman TestinonY. supra note 105.
156. National Toxicology Program "Known to be Huinan Carcinogens, g' Report on
Carcinogens," at http://ntp-server.niehs.nih.gov/htdocs/8-RoC/Known-ist.htnil (last visited
Apr. 5, 2001). Examples of chemotherapy drugs that are listed as "Known to be Human Car-
cinogens" include Busulfan, Cyclophasphamide, Melphalan. and Thiotepa. Id. See also De-
partment of Health and Human Services, National Toxicology Program "Reasonably Antici-
pared To Be a Human Carcinogen, r Report on Carcinogens," at htp://ntp-
server.niehs.nih.gov/htdocs/8_RoC/RAHC_list.html (last visited June 24. 2001). ELamples of
chemotherapy drugs that are listed as "Reasonably Anticipated To Be a I luman Carcinogens"
include BCNIJ and Cisplatin. Id.
157. National Toxicology Program-NTP Mission, available at http:I/nip-
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cancer patient may be poisoned with a known carcinogen (i.e. chemother-
apy), but it is too dangerous for the patient to take a drug that is only theo-
retically carcinogenic. In fact, therapies like Drs. Burzynski and Ivy's are
comprised of natural substances. Unlike chemotherapy, they are not listed as
carcinogens and no scientist has ever suggested that they are carcinogenic."'
B. Testing for Toxicity
Besides carcinogenicity, the FDA argues that because people can be in-
jured or killed from the toxicity of unapproved drugs, physicians and pa-
tients should not have the freedom to use these drugs."9 Apparently the FDA
believes that the same risk-benefit equation applies to every drug and every
disease. Such logic is sophistry.
For example, the FDA cites the thalidomide disaster as a reason to clini-
cally test every single drug."w Thalidomide was a sedative that was pre-
scribed to pregnant women to combat many of the symptoms associated with
morning sickness.' 6' This drug killed or produced catastrophic birth defects
in many children. 62 However, thalidomide was a sleeping pill and no one
dies from insomnia. The modest benefits of a good night sleep are out-
weighed by almost any risk. Therefore, requiring thorough and meticulous
clinical testing of a sleeping pill is appropriate and legitimate.
However, cancer is not insomnia. In the context of a cancer patient who
has been sent home to die or for whom orthodox therapies are ineffective,
the potential benefits of an unapproved treatment is not dying or not dying in
tremendous pain. The hypothetical risks that many cancer patients are will-
ing to endure for such benefits are enormous. Nonetheless, the FDA insists
server.niehs.nih.gov/main-pages/about-NTP.html (last visited June 24, 200 1).
The NTP is an interagency program consisting of relevant toxicology activities of
the National Institutes of Health's National Institute of Environmental Health Sci-
ences (NIH/NIEHS), the Centers for Disease Control and Prevention's National
Institute for Occupational Safety and Health (CDC/NIOSH), and the Food and
Drug Administration's National Center for Toxicological Research (FDA/NCTR)
Id.
158. National Toxicology Program "Known to be Human Carcinogens, (' Report on
Carcinogens," at http://ntp-server.niehs.nih.gov/htdocs/8_RoC/Known list.html (last visited
Apr. 5, 2001). There is no listing for Burzynski's therapy or its constituent agents. hi. See also
Department of Health and Human Services, National Toxicology Program "Reasonably All
ticipated To Be a Human Carcinogen, oh Report on Carcinogens," at http//rltp-
server.niehs.nih.gov/htdocs/8_RoC/RAHClist.html (last visited June 24. 2001). There is no
listing for Burzynski's therapy or its constituent agents. Id.
159. Patient Access to Alternative Treatnents-Friedman Testimony, supra note 105
160. Id.
161. Thalidomide Victims Ass'n of Can.-Ilone Page, available at
http://www.thalidomide.ca/wit.htm (last visited June 24, 2001).
162. Id.
210 I Vol. 38
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that treatments for insomnia and cancer must be subject to similar proce-
dures for clinical testing and approval."
In addition, clinical testing under the auspices of FDA approval does not
guarantee a drug's safety. For example, according to the New England Jour-
nal of Medicine, "the results of clinical trials submitted with an application
to the FDA to market a drug, cannot provide comprehensive information on
possible adverse events.""
C. Off-Label Use
Ironically, while most chemotherapy drugs are FDA-approved, many
are not approved for the specific cancers for which they are used.'" Over
time, and often with the urging of drug companies, these "off-label" uses be-
come part of the standard of care. In fact, none of the chemotherapy drugs
that are routinely used to treat childhood brain cancers are FDA approved for
children or for brain cancer."
D. Testing Naturally Occurring Substances
In addition to treating cancer like insomnia, the FDA treats laboratory
drugs the same as natural agents. The FDA states "[Ilt does not matter to
FDA (sic) whether a product is characterized as 'mainstream' or 'alterna-
tive'; it does not matter whether the product was synthesized in a state-of-
the-art laboratory or was found in the Brazilian rain forest."' Even herbs,
163. This criticism was inspired by the Congressional Testimony of Dr. Arnold Eggers
According to Dr. Eggers,
Cancer kills 500,000 people a year in the U.S. A one-year bureaucratic delay in
releasing a cure for cancer would necessarily kill 500,000. These are the people
who would still be alive if the government hadn't blocked their access to treatment
in their lifetime. These days, toxic side effects of drugs are quickly discovered and
publicized, or else extremely rare, and it is inconceivable that 500.000 people
could be killed by a dangerous new treatment before the alarm was called. I be-
lieve this arithmetic or statistical argument shows the error of the current system.
which guarantees that there will be a vast unnecessary loss of life if ever cancer is
cured.
Patient Access to Alternative Treatments: Beyond the FDA Before the Government Reform
Committee of the House of Representatives, 105h Cong. (Feb. 4, 1998) (statement of Arnold
Eggers, M.D.) available at http://www.house.gov/reformihearings/Ihealthcare/fda288/4ao.htm
2- (last visited Oct. 11, 2001).
164. G. A. Faich, Adverse-Drug-Reaction Monitoring. 314 Nimw ENG J Mij. 1589-92
(1986).
165. See, e.g., the chemotherapy drugs vincristine, cytoxan (i e. cyclophasplamide), eto-
poside, and cisplatin. PDR, supra note 152, at 773, 779. 1624.
166. Id.
167. Patient Access to Alternative Treatments-Friedman Testimony. supra note 105
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the FDA points out, can "pose serious risks."'68 This argument ignores two
critical points.
First, a substance that is part of human biology that cancer victims may
be missing (like Burzynski's peptides) is not the same as a synthetic labora-
tory formulation that has never existed before on the earth and has never
been introduced into the human body. The natural agent that a sick body is
missing does not pose the same variety of risks as a synthetic drug.
Secondly, the FDA ignores the hundreds of years of history and the
wealth of information regarding the application of herbs and other naturally
occurring agents to human disease.'69 While many naturally occurring sub-
stances can be dangerous or deadly, it is pure arrogance to insist that the ex-
isting, extensive knowledge regarding the safety and efficacy of certain natu-
ral agents in the treatment of cancer should be ignored.
E. Testing to Provide for Informed Decisions
The FDA maintains that without clinical testing, physicians and patients
cannot make informed choices regarding a treatment's benefits (i.e. effi-
cacy).'70 In the cancer context, this is a hypocritical argument. Under the ru-
bric of standard clinical testing, thousands of cancer patients are adminis-
tered drugs whose biological effects are not yet known."' In other words, it
is acceptable for patients to use their bodies as a living laboratory to test a
synthetic drug from a major pharmaceutical company, but it is not accept-
able for those same patients to try a naturally occurring agent prescribed by
their physician. In both scenarios, data can be collected on patient outcomes
and compared to the figures of patients who use orthodox treatments. In this
way, the results of using non-approved therapies can be calculated and com-
pared to standard treatments.
Finally, the FDA ignores the fact that a physician who has used a par-
ticular treatment is the expert on its application and use. While the treatment
may be new, and thus not routinely used, a small minority of physicians will
always be ahead of the rest. Such is the nature of medicine. Nonetheless, for
the FDA, this physician's experience, knowledge and expertise is trumped
by uninformed FDA bureaucrats. According to attorney Jonathan W. Emord,
"Your physician may recommend an experimental drug, the corporate spon-
sor of that drug may agree to supply it, and the clinical investigator may
agree to administer it, but if the FDA disagrees, you are out of luck."'""
168. Id.
169. See, e.g., HIILDEGARD VON BINGEN, PHYSICA (Pricilla Throop trans.. Healing Arts
Press 1998).
170. Patient Access to Alternative Treatments-Friedmnan Testimony, supra note 105
171. See NCI Clinical Trials-Understanding Trials, available at
http://cancertrials.nci.nih.gov/understandinglbasics/index.html#why (last visited June 24.
2001).
172. Patient Access to Alternative Treatments: Beyond the FDA Before the Government
[Vol. 38
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VI. Do BUREAUCRATS MAKE BETTER MEDICAL DECISION MAKERS
THAN A PATIENT'S PHYSICIAN?
All cancer sufferers are not the same. Age, state of health, type of can-
cer, type of cancer cell, spread of the cancer, and the spirit to live are differ-
ent for every individual."" As the eminent cancer surgeon William Osler
said, "Variability is the law of life, and as no two faces are the same, so no
two bodies are alike, and no two individuals react alike and behave alike un-
der the abnormal conditions which we know as disease."""'A Is it, therefore,
fair to assume that the appropriate people to choose an optimum cancer ther-
apy for an individual are FDA bureaucrats, judges or politically appointed
"cancer commissions"-people who have never met the patient, read his
medical history, or looked at his blood test, pathology report or x-ray? Many
patients and doctors argue that the individuals who are in the best position to
select a cancer therapy are the patient and their physician. Nonetheless, the
law currently favors the opinion of the bureaucrat or judge over that of the
patient's medical doctor.
For example, the California Health & Safety Code has been used to
permit the state to disapprove treatments for cancer by exercising its police
powers even "[w]here there is a genuine difference of medical opinion
among the experts on the question of whether a drug is generally recognized
as safe for the treatment of a particular disease.""' In other words, when
there is a disagreement as to the safety of a specific therapy for a specific pa-
tient, the position of a lawmaker trumps the opinion of the patient's doctor.
Why is this the law? The California Court of Appeal cited a 1969 Cali-
fornia Supreme Court case where a chiropractor treated a child with cancer
and the child died.1 6 The court argued that this was an "example of the kind
of tragedy which the state has a compelling interest to prevent."'" This ar-
gument resonates with the familiar theme that gullible cancer patients will
mistakenly choose the wrong therapy and, therefore, they must be protected
from their own naivet6 by a paternalistic government. However, this case
does not address the factual issue of how a bureaucrat can be a better medi-
cal decision maker than a patient's own medical doctor. For California to
cite as precedent a case where a chiropractor treated a patient for cancer
Reform Committee of the House of Represeniatives, 1056 Cong. (Feb. 4. 1998) lhcreinafter
Patient Access to Alternative Treatments-Enord Testimony] (statement of Jonathan W
Emord, Attorney).
173. HARRISON'S PRINCIPLES OF INTERNAL MEDIcINE 493-99 (Anthony S. Fauci, M.D.. et
al., eds., 1998).
174. William Osler Addresses: The Clinical Years, at http://www.shim.orgl-nunhanl
osler-homepage/clinical-years.htm (last visited Apr. 5, 2001).
175. People v. Privitera, 128 Cal. Rptr. 151, 158 (1976) (citing U.S. v. Article of Drug
Labeled (Box) Furestrol Vaginal Suppositories, 294 F. Supp. 1307, 1311 (D.C. Ga. 1968));
See CAL. HEALTH & SAFErY § 109345 (West 1996).
176. Privitera, 128 Cal. Rptr. at 159 (citing People v. PlulIps. 75 Cal. Rptr. 720 (1969)).
177. Privitera, 128 Cal. Rptr. at 159.
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clearly misses the point. Chiropractors are not medical doctors. In fact, ac-
cording to the California Labor Code, a chiropractor does not have any right
"to represent, advertise, or hold himself out as a physician."'78 Furthermore,
under the California Business & Professional Code, a chiropractor is not au-
thorized to practice "medicine, surgery, osteopathy, dentistry or optometry,
nor the use of any drug or medicine now or hereafter included in materia
medica. ' "'
The U.S. Supreme Court has confused the same issue. The Rutherford
court noted that "resourceful entrepreneurs" advertise a variety of "simple
and painless cures for cancer," designed to trick cancer victims. 8' If medical
doctors are "resourceful entrepreneurs" then why are they given a license to
practice medicine? If they are not "resourceful entrepreneurs," then this con-
cern does not apply to medical decisions made by patients with the help of
their medical doctor.
Is the U.S. Supreme Court challenging the competence of the medical
profession? Presumably, medical doctors are uniquely trained to render di-
agnostic and therapeutic assistance to their patients. Patients should therefore
be allowed to choose their medical doctor and expect that their doctor will
exercise sound judgment in selecting an appropriate treatment for their dis-
ease. There is no data to suggest that patients and doctors are more likely to
make mistakes if their list of cancer options is allowed to expand beyond
surgery, radiation, chemotherapy and hormone therapy. No such study has
ever been undertaken. This is especially ironic because the FDA continu-
ously purports the importance of using data in driving decisions. 8'
It is also useful to note that the federal government, not patients, has
filed nearly every lawsuit brought against physicians who used non-
approved cancer therapies.'82 Surely, if patients thought they had been
conned or exploited by "resourceful entrepreneurs" they or their estates
would have filed complaints.
A. The Folly of Centralized Decision Making
The folly of centralizing decision-making power becomes evident when
considering the numbers of patients involved. Even if one were to assume
that the FDA was in the best position to make medical decisions for every-
one, the FDA cannot play the role of physician to the half million cancer pa-
tients who will die this year. The absurdity of such centralized decision-
making is demonstrated with two examples.
178. CAL. LAB. § 3209.6 (West 2001).
179. CAL. Bus. & PROF. §§ 1000-1007 (West 2001).
180. U. S. v. Rutherford, 442 U.S. 544, 558 (1979).
181. Patient Access to Alternative Treatments-Friedman Testimony, supra note 105.
182. See, e.g., People v. Privitera, 128 Cal. Rptr. 151 (1976). U.S. v. Rutherford, 442
U.S. 544 (1979), and Koch v. Federal Trade Commission, 206 F.2d 311 (6th Cir. 1953)
[Vol. 38
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Zachary McConnell was in first grade when he was diagnosed with a
malignant brain cancer.' He endured surgery, chemotherapy and radiation,
but these highly toxic treatments made the boy dangerously sick.'" Like the
Kunnaris and the Horwins, Zachary's parents took their son to Dr. Burzyn-
ski's clinic in Houston, and his therapy appeared to be working. ," However,
on May 23, 1996, the FDA ordered Zachary off Burzynski's therapy, and
sent him back to chemo and radiation." The FDA asserted that the boy did
not fit the criteria of the protocol and that he could only receive the non-
approved therapy after the tumor returned.' Other Burzynski patients do-
nated their own medicine to help Zachary' 8 and the McConnells took their
plight to the media." The FDA finally reversed its decision and allowed the
boy back on the therapy.'" However, the two months that the child did not
receive the proper dose of the treatment had its effect and the tumor returned
in August 1996.' Zachary McConnell died in 1998.'
183. ELIAS, supra note 35, at 176-77. The cancer was a primitive neuroectodcrmal tumor
(PNET), a cancer identical or similar to medulloblastoma depending on its location. Id.
184. Id. at 181.
185. Id. at 183. Prior to starting the Burzynski therapy, a small speck appeared on an
MRI of Zachary's brain. The speck could have been scar tissue or a returning tumor. Within
two months of starting Burzynski's therapy, the speck had disappeared. Id.
186. Id. at 184. See also Patient Access to Alternative Treatnients-Emord Testimony,
supra note 171.
187. ELIAS, supra note 35, at 184.
188. Id
189. Id. at 185. According to their attorney, Jonathan W. Emord.
[The McConnells] hired Washington lawyers and a team of renowned scientific
experts, and they pled their case to the media and before Congress. begging for
help to reverse the FDA's decision. After a month and a half of constant, costly
and time-consuming effort, the FDA buckled under the pressure, relented, and re-
versed its decision.
Patient Access to Alternative Treatments: Beyond the FDA Before the Government Reform
Committee of the House of Representatives, 105' Cong. (Feb. 4. 1998) [hereinafter Patient
Access to Alternative Treatments-Emord Testinony] (statement of Jonathan W. Emord. At-
torney) available at http:/Iwww.house.gov/reform/hearingslhealthcare/fda29982__.4je.htm (last
visited June 23, 2001).
190. The FDA wrote a letter to Burzynski, "We are now able to conclude that Zachary
may have a very good prognosis .... We have determined that administration of antineoplas-
tons to Zachary may continue." ELIAS, supra note 35, at 185. Between the time the FDA or-
dered eight-year-old Zachary off the medicine and the time they allowed him back on the
medicine nothing had changed. According to Zachary's father, Shawn McConnell, "The only
things that happened were political and media pressure. Now we know these decisions aren't
based on science or the welfare of the patient. They're based on power and politics." Id. at
185-86.
191. Id. at 186.
192. Interview by Raphaele Horwin with Shawn McConnell, Scottsdale Arizona (May
1999). Zachary was eventually taken off Burzynski's therapy by his parents because the tu-
mor that reoccurred did not disappear after Burzynski was finally allowed to restart the ther-
apy. Surgery and radiation therapy was used. ELIAS, supra note 35, at 187-88.
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In the second example, Janet Isabella Cheadle was diagnosed with a ma-
lignant pediatric cancer called neuroblastoma when she was five years old.'"
She endured many months of high-dose chemotherapy and whole body ra-
diation. 9 ' The treatments took a tremendous toll on the child and her parents
sought to admit her to the Burzynski clinic. 9" The clinic told the parents that
this required FDA approval.19" The parents wrote a letter to the FDA's Con-
sumer Safety Officer and they received no response.'" Three weeks later, the
parents contacted another FDA representative who told them that they re-
quired a copy of Burzynski's protocol.'98 The protocol, sent via Federal Ex-
press, was rejected within five hours of receipt.'" Janet's parents called the
FDA's Consumer Safety Officer at his home and the officer claimed he had
no knowledge of the case." The parents were then referred to other FDA
employees."' According to congressional testimony, Janet's father, Dr. Lyle
Cheadle, "cried and begged" these bureaucrats to allow his daughter to be
treated with this non-toxic therapy."4 After fighting this bureaucracy for
months, Janet Cheadle was ultimately allowed to be treated by Dr. Burzyn-
ski.2"' Janet Isabella Cheadle is alive today.20 According to her father, all of
the other conventionally treated children who were diagnosed with neuro-
blastoma with Janet have passed away. 5 Dr. Cheadle continues to use a va-
riety of non-FDA therapies to treat his child.20 "If I waited for the FDA,
nothing would be done," Dr. Cheadle has stated.20
B. Can Terminal Patients Access Non-Approved Therapies?
The FDA contends that it is "committed to providing early access to
promising, but unproven, medical treatments for seriously ill patients who
might otherwise have no hope.""2 8 However, the FDA also states, "As com-
pelling as an individual case is, however, the cost of providing individual ac-
193. Patient Access to Alternative Treatments: Beyond the FDA Before the Government
Reform Committee of the House of Representatives, 10 5 h Cong. (Feb. 12, 1998) (statement of
Dr. Lyle Cheadle).
194. Id.
195. Id.
196. Id.
197. Id.
198. Id.
199. Id.
200. Id.
201. Id.
202. Id.
203. Telephone Interview with Dr. Lyle Cheadle (July 19, 2001).
204. Id.
205. Id.
206. Id.
207. Id.
208. Patient Access to Alternative Treatments-Friedman Testimony, supra note 105.
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cess cannot be to sacrifice the system that ultimately establishes whether
therapies are safe and effective."'
There is no program to allow cancer patients to have access to non-
approved therapies that are not undergoing clinical testing. The FDA, how-
ever, has two primary programs that theoretically allow a terminal cancer pa-
tient to have access to a non-approved therapy that is currently being tested.
The first is a called a "Treatment Investigational New Drug Application"
(IND)21 and the second has been termed a "Single Patient," "Emergency," or
"Compassionate IND."11
Both MIN's require that there must be no comparable treatment alterna-
tive.2 What does this mean? There is no case law on point, so currently it
means whatever the FDA decides. For example, as discussed supra, the FDA
has decided that chemotherapy is a comparable treatment alternative for ma-
lignant pediatric brain cancers even though oncologists admit it is ineffective
and toxic. Therefore, children like Alexander Horwin and Zachary McCon-
nell are not permitted access to an effective, non-toxic but unapproved ther-
apy such as Dr. Burzynski's treatment.
How many patients are given access to non-orthodox agents through an
IND? According to the Chairman of the House of Representatives Commit-
tee on Government Reform, "We know from the FDA's own records that in
1996, about 500 cancer patients were given access to an experimental drug
through the FDA, compared to half a million [cancer victims] who died that
year." 3 How many patients did the FDA turn down? The FDA claims that it
209. Id.
210. 21 C.F.R. § 312.34 (2001).
211. Patient Access to Alternative Treatments-Friedman Testimony, supra note 105.
212. 21 C.F.R. § 312.34(b) (2001).
Criteria. (1) FDA shall permit an investigational drug to be used for a treatment
use under a treatment protocol or treatment IND if:
(i) The drug is intended to treat a serious or immediately lifc-threatening disease;
(ii) There is no comparable or satisfactory alternative drug or other therapy avail-
able to treat that stage of the disease in the intended patient population;
(iii) The drug is under investigation in a controlled clinical trial under an IND in
effect for the trial, or all clinical trials have been completed; and
(iv) The sponsor of the controlled clinical trial is actively pursuing marketing ap-
proval of the investigational drug with due diligence.
21 C.F.R. § 312.34(b) (West 2001).
In respect to "Single Patient," "Emergency" or "Compassionate" IND's. the FDA's Michael
A. Friedman, M.D. has testified that these IND exceptions may be permitted when "other op-
tions do not exist." See Patient Access to Alternative Treatments-Friedman Testimony, suipra
note 105.
213. Patient Access to Alternative Treatments: Beyond the FDA Before the Government
Reform Committee of the House of Representatives, 1055 Cong. (Feb. 4. 1998) (statement by
Chairman Dan Burton).
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does not keep any data or records on the patients it turns down for single pa-
tient or emergency IND requests.1
VII. ADDRESSING THE ROLE OF ECONOMICS IN CANCER
Critically addressing the medical-policy arguments is crucial to creating
a political atmosphere where current FDA policy can be responsibly chal-
lenged and changed. There is another controlling factor, however, that must
also be addressed in order to inject integrity into lawmaking on this issue-
the role of economics in cancer.
A. The Critic's Perspective
Over the last fifty years, critics, including scientists, congressmen, phy-
sicians, and journalists, have alleged that despite the conflicting scientific
paradigms, economics plays a greater role than science in determining what
cancer therapies are ultimately available to the public." 5 According to Robert
E. Willner, M.D., Ph.D. 6 the pharmaceutical companies provide research
grants, contracts and advertising support that "guarantees virtual control over
scientific and medical direction and thought." ' 7 Dr. Wiliner states:
There are many simple non-toxic effective treatments for cancer. The cost
of providing them has been made impossible by the collusion between the
FDA and the pharmaceutical industry. The establishment has deliberately
used every imaginable and shameful tactic, some of which are even
"strong arm," to discredit, conceal[,j and destroy these therapies. The rea-
sons are clear. The pharmaceutical industry, which profits in the countless
billions from their infamous chemotherapy and all the drugs that usually
have to be taken to deal with the horrible "side-effects" would lose an
enormous income if the truth were known. 8
James P. Carter, M.S., M.D., agrees." 9 He has stated, "The FDA serves
as the pharmaceutical industry's watchdog which can be called upon to at-
214. Patient Access to Alternative Treatments-Friedman Testimony. supra note 105.
215. For an example of scientists: Dr. Linus Pauling and Dr. Samuel Epstein; for an ex-
ample of congressmen: Mr. Berkley Biddel and Mr. Dan Burton; for an example of a physi-
cian: Dr. Robert Willner; for an example of journalists: Barry Lynes and G. Edward Griffin.
See also BARRY LYNES, THE HEALING OF CANCER: THE CURES-THE COVER-UPS AND TIi.h
SOLUTION Now (1989); and G. EDWARDGRIFFIN, WORLD WITHOUT CANCER (13" prtg. 1998).
216. The resume of Robert E. Willner, M.D., Ph.D. includes: Fellow of the American
Board of Pain Management, Fellow of the American Academy of Neurologic and Orthopedic
Medicine and Surgery, certified by the American Board of Family Physicians, Diplomat of
the American Board of Family Medicine, member of the Board of Directors of the American
Academy of Advancements in Medicine, Executive Secretary of the American Physicians As-
sociation. ROBERT E. WILLNER, M.D., PH.D., THE CANCER SOLUTION 299-303 (1994).
217. Id. at 5.
218. Id. at 19-20.
219. Dr. Carter has a medical degree from Northwestern University and a masters of sci-
ence degree in Parasitology from Columbia University. Fie is a professor at Tulane University
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tack and destroy a potential competitor, under the guise of protecting the
public." '  A leading cancer expert, Samuel S. Epstein, M.D.,!' concurs:
For decades, the war on cancer has been dominated by powerful groups of
interlocking professional and financial interests, with the highly profitable
drug development system at its hub .... The members of the generously
funded cancer establishment include the NCI, ACS [American Cancer So-
ciety], the comprehensive cancer centers such as New York's prototypical
Memorial Sloan-Kettering, whose annual budget exceeds S350 million,
NCI and ACS contractees and grantees at universities, and major pharma-
ceutical companies. Cancer care is big business, with annual cancer drug
sales of approximately $10 billion.22
Medical doctors are not alone in suggesting a link between the interests
of the pharmaceutical industry and the cancer treatments that are accessible.
Congressional Investigations have also reported that collusion may exist. For
example, in 1953, United States Senator Charles Tobey, Chairman of the In-
terstate and Foreign Commerce Committee, directed Benedict F. Fitzgerald,
Jr. to conduct an investigation to determine whether a conspiracy existed to
suppress innovative cancer treatments. Fitzgerald was special counsel to the
Senate Committee on Interstate and Foreign Commerce, a seasoned attorney
and investigator with years of experience in uncovering price-fixing and
monopolistic practices by major industries. On August 3, 1953, a summary
of his report was entered into the Congressional Record Appendix. Fitzger-
ald stated:
My investigation to date should convince this committee that a conspiracy
does exist to stop the free flow and use of drugs in interstate commerce
which allegedly has solid therapeutic value. Public and private funds have
been thrown around like confetti at a country fair to close up and destroy
clinics, hospitals, and scientific research laboratories which do not con-
form to the viewpoint of medical associations.'
Forty-five years later, in 1998, Congressman Dan Burton testified:
The FDA dictates what treatments doctors can use in treating serious ill-
nesses, but most of those are toxic and often dangerous to already weak-
School of Public Health and Tropical Medicine and has served as a consultant to the World
Health Organization. JAMES P. CARTER, M.S., M.D., RACKETEERING LN MEDICLNE: TE
SuPPREssIoN OF ALTERNATIVES (1993).
220. Id. at 179.
221. Samuel S. Epstein, M.D. is Professor of Occupational and Environmental Medicine
at the School of Public Health, University of Illinois Medical Center at Chicago. Dr. Epstein
is past chairman of the Air Pollution Control Association Committee on Biological Effects of
Air Pollutants; President of the Society of Occupational and Environmental Health: and foun-
der and secretary of the Environmental Mutagen Society. He has written over 250 scientific
articles and ten books. SAiuELS. EPSTEN, M.D., THE POLMCS OF CANCER REvIsITED (1998).
222. Id. at 367-69.
223. A Report to the Senate Interstate Commerce Committee on the Need for Investiga-
tion of Cancer Research Organizations, 83 CONG. REC. (1953).
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ened patients. Meanwhile, our government agencies spend untold billions
of dollars trying to find elusive cures [and] the FDA has harbored a culture
of intimidation and sometimes harassment against those looking for alter-
native cures.224
B. Clinical Testing Translates Into Pharmaceutical Industry Control
While some type of collusion may exist to enable major drug companies
to "comer the market" on cancer treatments, such a conspiracy is not neces-
sary. Basic economics can produce the same results. For example, the FDA
admits that "[m]ost new therapies today reach the market because a private
commercial entity was willing to invest in the development and testing proc-
ess necessary to bring a product to the market." ''2 In fact, the cost of bringing
a new drug to market has been estimated to be between $250 to $500 mil-
lion22 with the average being $313 million.227 Therefore, pharmaceutical
companies have an incentive to finance, test, and market only those drugs
that they can ultimately patent. To go to the expense to develop and market a
drug they cannot patent, no matter how efficacious, would be a foolish ex-
penditure of money that they could never recoup. In this way, the require-
ment to use clinical testing for all cancer therapies, and the great costs it en-
tails, leads to eliminating from the market unprofitable, but potentially safe
and effective therapies. According to Congressman Berkley Bedell, "It costs
millions and millions of dollars to go through the FDA approval process.
This freezes out anyone except giant corporations, and makes it utterly im-
possible for any low cost non-patentable medicines to get into the system." '28
For example, the NCI has stated that Dr. Burzynski's therapy works for
brain tumors. 229 Other oncologists concur.3 ' In addition, the standard thera-
pies for brain tumors (chemotherapy and radiation) are ineffective and catas-
trophically debilitating in young children.' Nonetheless, Burzynski's ther-
apy, comprised of administering specific polypeptides that most healthy
people have in their blood, is still not FDA approved. One reason for this
224. Patient Access to Alternative Treatments: Beyond the FDA Before the Government
Reform Committee of the House of Representatives, 10 5h Cong. (Feb. 4. 1998) (statement by
Chairman Dan Burton).
225. Patient Access to Alternative Treatments-Friedman Testinony, supra note 105.
226. Barbara Sibbald, Making a Case for a $2700-a-Month Drug, CAN. MtD. Ass'N J.,
available at http://www.cma.ca/cmaj/vol- 16 1/issue-9/ 173.htm (last visited Sept. 26, 2001).
227. Dennis Cauchon, High Price, High Hopes for Cancer Drug, USA TODAY, Nov. 24.
1999, available at http://www.usatoday.com/life/health/drugs/lhdru075.htm (last visited Sept.
26, 2001).
228. Patient Access to Alternative Treatments: Beyond the FDA Before the Government
Reform Committee of the House of Representatives, 105 'h Cong. (Feb. 4, 1998) (statement of
the Hon. Berkley Bedell).
229. Memorandum from Dr. Michael Friedman, supra note 120.
230. The Burdick Report, supra note 118.
231. See Friedman, supra note 112, Weil supra note 113, S. Attard-Montalto. supra note
114, Geyer, supra note 115, and Finlay, supra note 117.
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may be that these peptides, which the NCI has called "well defined pure
chemical entities,""2 do not require genetic engineering or creative chemis-
try. And because they are naturally occurring substances, they cannot be pat-
ented to the same degree as novel synthetic drugs.?" As a result, pharmaceu-
tical companies would not be able to control the market and pricing of these
"pure chemical entities." Any profits they would gain would be dramatically
less than the profit margins from the drugs that they can control through
their patents. Increasing the accessibility of Dr. Burzynski's therapy would,
therefore, translate into decreased market share for the treatments that enjoy
higher profit margins (i.e. chemotherapy).
The figures involved in the cancer drug industry are not insubstantial.
According to one estimate, treatment for brain tumors alone represents S3.8
billion.' Therefore, in the final economic analysis, the large drug companies
would be financially justified to not finance the testing of therapies like
Burzynski's, regardless of their safety and efficacy. In fact, in our free mar-
ket economy, large drug companies would be justified to use their powerful
lobbying resources to dissuade lawmakers from passing any law that would
allow patients to access such non-patentable therapies that could cause them
to lose substantial market share. Given these economic realities, even the
FDA asserts that something must be done to create market incentives to test
nonpatentable products.235
VIII. CONCLUSION
The FDA contends that their regulations in respect to cancer drugs,
treatments and therapies exist to protect cancer patients from unscrupulous
quacks. But such a position is incongruous when the issue is whether pa-
tients should be permitted to have therapies that their medical doctors rec-
ommend. Physicians are licensed professionals who should be allowed to
treat patients as they see fit without government interference. And patients
are already protected from quackery by medical malpractice laws that re-
quire professional competence and informed consent.
Why should terminal patients, who according to orthodox medicine will
die, be prevented from accessing non-orthodox therapies through their medi-
cal doctor? The worst scenario is that the modality shortens their life. If,
however, the patient is able to exercise informed consent, understand that the
treatment is not FDA approved and that there are no guarantees in respect to
232. Memorandum from Dr. Michael Friedman. supra note 120.
233. A naturally occurring substance itself cannot be patented; only the process to manu-
facture it can be protected. However, in this case, the process to manufacture peptides is rela-
tively simple, making this manufacturing aspect financially unattractive.
234. KS Biomedix Brain Cancer Drug Vins Fast-Track Status. Reuters Medical News.
Aug. 6, 2001, available at httpl/oncology.medscape.comlreuters/profl2-001108/
08.07/20010806rglt007.html (last visited Aug. 11, 2001).
235. Patient Access to Alternative Treatnents-Friedman Testimony. supra note 105.
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the risks or benefits, why should the patient be prevented from exercising
that choice?
A more plausible reason for the FDA's actions is that this bureaucracy
has become unduly influenced by the multi-billion dollar drug industry. This
industry stands to lose a great deal if the FDA would allow access to drugs
that these manufacturers do not control. But whatever the reason, the FDA's
position is unsupportable on medical policy grounds.
Dr. Benjamin Rush, physician and signer of the Declaration of Inde-
pendence said:
Unless we put medical freedom into the Constitution, the time will come
when medicine will organize itself into an undercover dictatorship. To re-
strict the art of healing to one class of men and deny equal privileges to
others will constitute the Bastille of medical science. All such laws are un-
American and despotic.2 36
Medical freedom was not written into the constitution, and today, there
are a growing number of people, including physicians, who would argue that
Dr. Rush's prophecy has been fulfilled.
My innocent son, Alexander, bore the brunt of that despotism. Like
many other parents, my wife and I were not allowed to exercise the most
fundamental right as mother and father-the right to try to save the life of
our child. By interfering with this moral, ethical and legal right and obliga-
tion, our government demonstrated its despotism. Ironically, this country
was founded to escape tyranny. Freedom has been America's hallmark and it
is this freedom that has made our country grow and prosper. Our Declaration
of Independence states "that all men are created equal, that they are endowed
by their Creator with certain unalienable Rights, that among these are Life,
Liberty, and the pursuit of Happiness." '37 Because life is an unalienable right,
individuals must be free to maintain their life when disease strikes them.
Without the freedom to live, every other right our country bestows is mean-
ingless.
"I say RIGHTS, for such [the people] have, undoubtedly, antecedent to all
earthly government,-Rights, that cannot be repealed or restrained by
human laws-Rights, derived from the great Legislator of the universe.
- John Adams. 8
236. Future of Medicine: Medical Freedom and the Politics of Health Care available at
http://www.altemativemedicine.com/digest/issue0 1/0101 5R00.html (last visited July 4. 2001)
citing BENJAMIN RUSH, THE AUTOBIOGRAPHY OF BENJAMIN RUSH; His TRAVELS THROUGH
LIFE TOGETHER WITH HIS COMMONPLACE BOOK FOR 1789-1813 (Greenwood Publishing
Group, 1970) (1948).
237. THE DECLARATION OF INDEPENDENCE para. 2 (U.S. 1776).
238. JOHN ADAMS, A DISSERTATION ON THE CANON AND FEUDAL LAW (1765), available
at http://www.ashbrook.org/library/18/adams/canonlaw.html (last visited Oct. 2. 2001).
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